The role of miR-4284 in cancer progression and therapeutic response: Regulatory mechanisms and clinical implications
Chenhao Liang , Yaojie Feng , Yuhua Zhang , Zehua Wang , Xinming Su , Shiwei Duan
Malignancy Spectrum ›› 2025, Vol. 2 ›› Issue (2) : 59 -73.
The role of miR-4284 in cancer progression and therapeutic response: Regulatory mechanisms and clinical implications
As a pivotal microRNA (miRNA), miR-4284 exhibits noteworthy aberrant expression levels across various cancers and diseases, exerting a crucial role in modulating cancer progression and prognosis. This article endeavors to comprehensively elucidate the regulatory mechanisms of miR-4284 in cancer, delving deeply into its impact on tumor cell proliferation, invasion, and metastasis by intervening in key signaling pathways such as p65, mitogen-activated protein kinase (MAPK), and transforming growth factor-β (TGF-β). Moreover, this article examines the potential associations of miR-4284 with diverse current therapeutic strategies, such as cancer prediction models, synergistic effects of chemotherapeutic agents, mechanisms of ultrasound-targeted microbubble destruction technology, and enhancement of radiotherapy. However, despite the significant strides made in miR-4284 research, certain limitations persist. Looking ahead, we anticipate that larger-scale and more in-depth studies will further unveil the functional mechanisms of miR-4284 and elucidate its role in therapeutic drug efficacy, thus furnishing robust theoretical underpinnings for the clinical application of miR-4284.
miR-4284 / cancer progression / signaling pathways / therapeutic response / tumor invasion and metastasis
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
|
| [65] |
|
| [66] |
|
| [67] |
|
| [68] |
|
| [69] |
|
| [70] |
|
| [71] |
|
| [72] |
|
| [73] |
|
| [74] |
|
| [75] |
|
| [76] |
|
| [77] |
|
| [78] |
|
| [79] |
|
| [80] |
|
| [81] |
|
| [82] |
|
| [83] |
|
| [84] |
|
| [85] |
|
| [86] |
|
| [87] |
|
| [88] |
|
| [89] |
|
| [90] |
|
The Author(s). Malignancy Spectrum published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.
/
| 〈 |
|
〉 |